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Compassionate Use Programs or Phase IV Trials of
Innovative Molecular Targeted Drugs in Lung Cancer
Deal or No Deal?
Wilfried Eberhardt, MD
PHASE IV OPEN-LABELED STUDY WITH ERLOTINIB IN SOUTH-EAST
ASIANS WITH NON-SMALL CELL LUNG CANCER
In this month’s issue of the journal, we are faced with yet another large compassionate
use program (expanded access program [EAP/phase IV trial]) with a molecular targeted drug
in patients with non-small cell lung cancer (NSCLC).1 This time, Mok et al.1 present the
results of a large South-East Asian patient cohort treated within an expanded access
program of erlotinib for NSCLC in multiple-line situations after chemotherapy and/or
radiotherapy or upfront in patients unsuitable for standard combination chemotherapy.
Interestingly, 1242 patients were investigated for safety and efficacy of the treatment with
the EGF-R tyrosine kinase inhibitor erlotinib in this mature analysis of the clinical trials
results. The median overall survival with more than 14 months and the median progres-
sion-free survival (PFS) of nearly 6 months seen with erlotinib in South-East Asian
patients were found to be significantly better than the results observed in the parallel
TRUST program with erlotinib in white/non-Asian patients reported in the same issue of
this journal.2 The overall safety profile of drug administration among South-East Asian
patients was excellent and did not show any specific toxicities and does not imply any note
of caution as serious toxicities were registered extremely rare with this agent—especially
when considering the poor prognostic groups selected here with multiple prior treatments.
Probably based on learning effects, only 14% of patient had to be dose reduced in this
EAP comparable with what had already been observed with other EGF-R tyrosine kinase
inhibitor such as gefitinib and vandetanib in large phase II, phase III studies, or phase IV
trials.3–10 Thus, both toxicity profiles and efficacy results are in line to what has already
been reported for the even larger EAP for gefitinib performed from 2002 to 2007.6
WHAT CAN WE LEARN FROM THIS COMPASSIONATE USE
PROGRAM WITH ERLOTINIB?
1. If larger and more unselected patient populations are treated with such an innovative
drug, population pharmacogenomics and pharmacokinetics may lead to more het-
erogeneity in both treatment and toxicity effects. Larger populations may also reveal
rare but significant side effects as known for other innovative agents (e.g., rhabdo-
myolysis, agranulocytosis, aplastic anemia, or interstitial pneumonia). Also specific
interactions with significant comorbidities of the patients with lung cancer may be
revealed in such a large phase IV population. Interestingly, neither could be
observed for erlotinib in this setting, which confirms the advantageous safety profile
for this agent in the enrolled South-East Asian population.1
2. Efficacy of this EGF-R acting drug erlotinib in South-East Asian patients is
confirmed by the high percentage of 27% objective responses among the 1118
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patients evaluable for response.1 Definitely, this result is
based on the considerably higher EGF-R mutation rate
in the South East Asian population compared with
whites (27% in South-East Asians versus 10% in whites
seems to be in line with other epidemiological data on
this issue). No data on EGF-R mutation status are
provided for this large group of patients included into
the phase IV study. Other phase III trials in first or
multiple line have been significantly more successful in
determining the EGF-R mutation status of their in-
cluded patient population.11,12 With activating EGF-R
mutations now proven to be a predictive biomarker for
PFS under first-line EGF-R treatment, gathering of such
datasets is of considerable importance, especially in
those with multiple prior therapies.12
3. Those patients developing rash (grade 2) under treat-
ment with erlotinib represent a favorable group of
patients with a significantly improved survival progno-
sis concerning both overall survival and PFS. This
finding has already been observed among Western/
white populations under treatment with erlotinib and is
confirmed in this study for the first time also among
South-East Asians.2 Whether indicating subgroups with
a generally improved survival prognosis or really rep-
resenting predictive impact by this clinical parameter
cannot be derived from such a single-arm phase IV trial
setting. A note of caution has to be mentioned for all
treatment-related/dependent factors as there is consid-
erable interaction possible with the treatment and/or
toxicities and significant risk of selection bias within
such a clinical research setting. Statistical issues are
much more complex for these treatment-related/depen-
dent factors, and further research should be made also
on the statistical background and interpretation of such
trials results.
PHASE IV EAPS WITH NEW DRUGS—DEAL OR
NO DEAL?
Within recent years, we have had the privilege to
administer new and innovative drugs in thoracic cancers
within large compassionate use programs/open-labeled phase
IV studies. Examples include (1) gefitinib in multiple-line
NSCLC,6 (2) bevacizumab in advanced NSCLC (Studying
Avastin in Lung [SAIL]),10 (3) pemetrexed in malignant
mesothelioma,13 and (4) finally, recently erlotinib in ad-
vanced NSCLC (TRUST).1,2
Generally, there are significant pros and cons for such
phase IV studies, which are summarized in this study.
Pros
1. With new and active agents entering the clinical re-
search setting and showing encouraging results regard-
ing treatment responses and/or toxicity reductions
within phase II, late randomized phase II, or phase III
trials, both patients and physicians are generally eager
to use these new agents in situations where significant
need for active treatment exists. Clearly, there is a
considerable unmet need for alternative treatments
when first-, second-, and third-line approaches in ad-
vanced cancers have already been administered or even
failed.
2. Before formal registration and/or formal reimbursement
of expensive innovative agents, these large EAPs/open-
labeled phase IV trials have an important economical
impact within the health care systems. Study drugs for
these phase IV trials are usually supplied by the phar-
maceutical companies and do not have to be paid for by
the health care system or insurance companies. The
overall economical impact of these settings should not
be underestimated.
3. Formal registration of new drugs by the responsible
agencies in different countries (e.g., Food and Drug
Administration and European Medicines Agency) usu-
ally takes some time, and study drug availability typi-
cally proceeds sequentially over continents and coun-
tries. For an individual patient with advanced disease,
treatment with a beneficial new agent is urgent and
cannot be delayed. For some patients, formal registra-
tion and availability of the drug may come too late.
Therefore, large phase IV trials represent a means to
deliver new drugs to large patient populations with
significant need for the specific innovation.
4. Open-labeled phase IV trials are of major importance
for population pharmacology, pharmacokinetics, phar-
macogenomics, and population-based toxicity analysis
of new drugs. Especially, significant rare toxicities may
be revealed with larger populations at risk in these
trials.
Cons
1. Within phase I, phase II, and phase III trials, patients are
strictly selected based on specific inclusion and exclu-
sion criteria. For phase IV trials, these criteria are
usually opened up to wider patient groups. Significant
interaction with specific patient comorbidities and even
patient comedications may be the consequence. If these
factors and parameters are not strictly documented and
monitored in the phase IV study, potentially higher risks
for the individual patient may be the natural conse-
quence.
2. Patients within phase I, phase II, and phase III trials
typically require review of histopathology or selection
based on histopathological or molecular pathologic bi-
omarkers. Strict availability of diagnostic specimen is
nowadays usually a prerequisite to enter preregistration
trials with new molecular targeted agents. For phase IV
studies, typically these strict inclusion requirements do
not exist. As a consequence, the presented very large
datasets often do not help to further identify patient
selection criteria for a new drug.
3. Large phase IV trials or compassionate use programs
are not always published as early as possible, when
compared with preregistration phase I, phase II, or
phase III trials. Publication of this experience of a new
drug administered to very large patient populations
should be more strongly encouraged by the participat-
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ing investigators or coordinating investigators. More-
over, journals should not focus on pivotal phase I,
randomized phase II, and phase III trials for publication
only. Large experience with an innovative drug within
an open-labeled phase IV study represents significant
information concerning activity/toxicity/safety of the
new agent with considerable impact on physicians look-
ing for alternative treatments in their patients.
WHAT WOULD BE THE PERFECT DEAL FOR AN
IDEAL OPEN-LABELED PHASE IV STUDY?
1. Strict inclusion of patients only with recent pathologic
specimen available and with informed consent to inves-
tigate prognostic/predictive biomarkers and to generate
important findings for translational research projects
(compared with phase I, phase, II or phase III trials with
significant impact on registration).
2. Clearly and well-defined inclusion/exclusion criteria of
the phase IV trial.
3. More extensive documentation of patient’s (a) prognos-
tic factors; (b) significant other factors (e.g., smoking
status); (c) comorbidities (e.g., renal and hepatic func-
tion); and (d) comedications to better define the in-
cluded patient population.
4. For some drugs, it may even be of importance to
perform investigations on population pharmacogenom-
ics (e.g., individual gene polymorphisms).
5. Informed consent to allow longer follow-up of long-
term survivors of the phase IV including investigations
on specific long-term toxicities (e.g., renal, hepatic,
bone marrow, neuropathy, cardiac, pulmonary, cutane-
ous, and endocrine).
CONCLUSIONS
Open-labeled phase IV trials/compassionate use pro-
grams with new agents in thoracic cancers such as the one
reported in this study by Mok et al. and Reck et al.1,2 for
advanced NSCLC represent an important part of the clin-
ical drug research and development program necessary to
safely and effectively introduce innovative agents later
into the standard of care management for these individual
cancers.
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